Merck (MRK) closed the most recent trading day at $86.39, moving -0.24% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 4.84% for the day. Meanwhile, the ...

Research analysts at Zacks Research lowered their Q4 2026 EPS estimates for shares of Merck & Co., Inc. in a report released ...

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

Research analysts at Zacks Research reduced their Q1 2026 EPS estimates for shares of Merck & Co., Inc. in a research note issued to investors on Tuesday, April 1st. Zacks Research analyst S. Ganoria ...

Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Company (MRK – Research Report) yesterday and set a price target of ...

TD Cowen analyst Steve Scala maintained a Hold rating on Merck & Company (MRK – Research Report) today and set a price target of $100.00.

Merck secures global rights to HRS-5346, an investigational Lp(a) inhibitor, in a deal with Hengrui Pharma worth up to $1.97 billion.

But AstraZeneca stock fell in line with pharma stocks. Merck (NYSE:MRK) recently presented promising results from the Phase 3 ZENITH trial for its drug WINREVAIR, but the company's stock ...

If you are looking for an AI stock that is more promising than MRK but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.